Drug reference

enasidenib

Mosby’s 2024 Nursing Drug Reference

Source: Mosby’s 2024 Nursing Drug Reference
PDF pages: 468, 469

Review source pages for extracted sections and age labels.

Overview

Names and pronunciation

(en′-a-sid′-a-nib) IDHIFA

PDF page 468

Functional class

Func. class.: Antineoplastic, isocitrate dehydrogonase-2 inhibitor

PDF page 468

Uses

USES: Relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutation

PDF page 469

Safety

Warnings and precautions

Black Box Warning: Differentiation syn- drome • Adult: PO: 100 mg/day until disease progression. Treat those without dis- ease progression for a minimum of 6 mo to allow time for clinical response

PDF page 469

Dose and formulations

Dosage and routes

DOSAGE AND ROUTES

PDF page 469

Available forms

Available forms: Tablets 50, 100 mg

PDF page 469

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

enasidenib

Mosby’s 2024 Nursing Drug Reference

Source: Mosby’s 2024 Nursing Drug Reference
PDF pages: 468, 469

Review source pages for extracted sections and age labels.

Overview

Names and pronunciation

(en′-a-sid′-a-nib) IDHIFA

PDF page 468

Functional class

Func. class.: Antineoplastic, isocitrate dehydrogonase-2 inhibitor

PDF page 468

Uses

USES: Relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutation

PDF page 469

Safety

Warnings and precautions

Black Box Warning: Differentiation syn- drome • Adult: PO: 100 mg/day until disease progression. Treat those without dis- ease progression for a minimum of 6 mo to allow time for clinical response

PDF page 469

Dose and formulations

Dosage and routes

DOSAGE AND ROUTES

PDF page 469

Available forms

Available forms: Tablets 50, 100 mg

PDF page 469

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.